Reducing the risk of late recurrence in hormone-responsive breast cancer

Annals of Oncology

Volumn 18, Issue SUPPL. 8, 2007, Pages

  Cufer T ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Breast cancer; Extended adjuvant therapy; Hormone responsive; Recurrence

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; MEGESTROL ACETATE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE;

ADJUVANT THERAPY; ARTHRALGIA; BONE DENSITY; BONE DISEASE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; EVIDENCE BASED MEDICINE; FRACTURE; HIGH RISK PATIENT; HORMONE RESPONSIVE BREAST CANCER; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE MODIFICATION; LIPID METABOLISM; LONG TERM EXPOSURE; MASTECTOMY; METASTASIS INHIBITION; MYALGIA; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RECURRENT CANCER; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SWEATING; THROMBOEMBOLISM; TREATMENT DURATION; VAGINA BLEEDING; VAGINAL DRYNESS; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; METABOLISM; NEOPLASM; REVIEW; RISK FACTOR; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; TAMOXIFEN; TRIAZOLES;

EID: 38549095771     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm262     Document Type: Conference Paper

References (34)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717.
2. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93: 684-690.
3. Buzdar A, Jonat W, Howell A et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 1996; 14: 2000-2011.
4. Dombernowsky P, Smith I, Falkson G et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453-461.
5. Gershanovich M, Chaudri HA, Campos D et al. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 1998; 9: 639-645.
6. Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18: 1399-1411.
7. Bonneterre J, Buzdar A, Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92: 2247-2258.
8. Buzdar A, Douma J, Davidson N et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001; 19: 3357-3366.
9. Paridaens R, Dirix L, Lohrisch C et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003; 14: 1391-1398.
10. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21: 2101-2109.
11. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
12. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262-1271.
13. Ingle JN, Tu D, Pater JL et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006; 99: 295-300.
14. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14: 2738-2746.
15. Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001; 93: 456-462.
16. Stuart NS, Warwick J, Blackledge GR et al. A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer. Eur J Cancer 1996; 32A: 1888-1892.
17. Gale KE, Andersen JW, Tormey DC et al. Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. Cancer 1994; 73: 354-361.
18. Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17. J Clin Oncol 2006; 24: 3629-3635.
19. Wasan KM, Goss PE, Pritchard PH et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005; 16: 707-715.
20. Jakesz R, Samonigg H, Greil R et al. ABCSG. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol 2005; 23: 10s [abstract 527].
21. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455-462.
22. Coombes RC, Hall E, Gibson LJ et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092. Erratum in: N Engl J Med 2004; 351: 2461.
23. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
24. Thürlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-2757.
25. Whelan TJ, Goss PE, Ingle JN et al. Assessment of quality of life in MA.17: A randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005; 23: 6931-6940.
26. Rieber AG, Theriault RL. Aromatase inhibitors in postmenopausal breast cancer patients. J Natl Compr Canc Netw 2005; 3: 309-314.
27. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005; 23: 619-629.
28. Goss PE. MA.17 Collaborative Trialists. Post-unblinding analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs. placebo): Updated analysis. Eur J Cancer Suppl 2006; 4: 109 [abstract 209].
29. Robert NJ, Goss PE, Ingle JN et al. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post-unblinding. J Clin Oncol 2006; 24: 15s [abstract 550].
30. Normanno N, Di Maio M, De Maio E et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005; 12: 721-747.
31. Goss PE, Ingle JN, Tu D. NCIC CTG MA.17: Updated analysis on disease free survival (DFS) according to estrogen receptor and progesterone receptor status of the primary tumor. Eur J Cancer Suppl 2006; 4: 149 [abstract 350].
32. Dowsett M, Cuzick J, Wale C et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study. J Clin Oncol 2005; 23: 7512-7517.
33. Viale G, Regan M, Dell'Orto P et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 2005; 94 (Suppl 1): S13 [abstract 44].
34. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042-4057. Erratum in: J Clin Oncol 2004; 22: 1351.